Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Leases (2019 - 2026)

Oramed Pharmaceuticals filings provide 7 years of Operating Leases readings, the most recent being $540000.0 for Q4 2025.

  • Quarterly Operating Leases rose 246.15% to $540000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $540000.0 through Dec 2025, up 246.15% year-over-year, with the annual reading at $540000.0 for FY2025, 246.15% up from the prior year.
  • Operating Leases hit $540000.0 in Q4 2025 for Oramed Pharmaceuticals, down from $589000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.1 million in Q1 2022 and bottomed at $120000.0 in Q1 2025.
  • Average Operating Leases over 5 years is $512350.0, with a median of $518500.0 recorded in 2021.
  • The largest annual shift saw Operating Leases surged 1619.35% in 2021 before it tumbled 61.74% in 2023.
  • Oramed Pharmaceuticals' Operating Leases stood at $504000.0 in 2021, then soared by 77.38% to $894000.0 in 2022, then tumbled by 61.74% to $342000.0 in 2023, then tumbled by 54.39% to $156000.0 in 2024, then skyrocketed by 246.15% to $540000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Operating Leases are $540000.0 (Q4 2025), $589000.0 (Q3 2025), and $648000.0 (Q2 2025).